Actym Therapeutics, Inc.: Funding, Investors & Team (Sep 2026)
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.
Actym Therapeutics, Inc. has raised $70.7M across 3 funding rounds on record, the most recent a Series A of $25.5M announced in Oct 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Actym Therapeutics, Inc. Company Profile and Key Stats
Latest funding round on record: Oct 2023.
Actym Therapeutics, Inc. Funding Rounds
Actym Therapeutics, Inc. raised $34.0M in an undisclosed round announced in Apr 2020.
3.3 years later, an undisclosed round of $11.2M was announced in Jul 2023.
3 months later, a Series A of $25.5M was announced in Oct 2023.
Actym Therapeutics, Inc. Founders and Leadership Team
Contact details for the Actym Therapeutics, Inc. team: 1 of 1 has an email address on file.
Start 14-day free trial →Actym Therapeutics, Inc. Funding Compared to Other Biotechnology Startups
Actym Therapeutics, Inc.'s latest round of $25.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Actym Therapeutics, Inc. in Biotechnology and Berkeley
Companies Similar to Actym Therapeutics, Inc.
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
Actym Therapeutics, Inc. Funding FAQs
What does Actym Therapeutics, Inc. do?
Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.
How much funding has Actym Therapeutics, Inc. raised?
Actym Therapeutics, Inc. has raised $70.7M across 3 rounds on record. The most recent is a Series A of $25.5M announced in Oct 2023.
When did Actym Therapeutics, Inc. last raise funding?
Actym Therapeutics, Inc.'s most recent funding round on record is a Series A of $25.5M, announced in Oct 2023.
Who is the CEO of Actym Therapeutics, Inc.?
Christopher Thanos is listed as CEO at Actym Therapeutics, Inc..
Where is Actym Therapeutics, Inc. headquartered?
Actym Therapeutics, Inc. is based in Berkeley, California, United States.
How many employees does Actym Therapeutics, Inc. have?
Actym Therapeutics, Inc. is in the 11-50 employee band.
How does Actym Therapeutics, Inc.'s funding compare to other Biotechnology startups?
Actym Therapeutics, Inc.'s latest round of $25.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Actym Therapeutics, Inc. Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Actym Therapeutics, Inc. is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.